Related Experiment Video
Updated: Sep 3, 2025
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Recommendations on phenylketonuria in Turkey
Turgay Coşkun1, Mahmut Çoker2, Neslihan Önenli Mungan3
1Division of Pediatric Metabolism and Nutrition, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara.
Insights
Phenylketonuria (PKU) management in Turkey requires standardized diagnosis and treatment thresholds. Expert recommendations emphasize early intervention, specific phenylalanine (Phe) level targets, and tailored L-amino acid supplementation for optimal patient outcomes.
Area of Science:
- Genetics and Metabolic Disorders
- Pediatric Medicine
- Clinical Practice Guidelines
Background:
- Phenylketonuria (PKU) is an autosomal recessive disorder impacting phenylalanine (Phe) metabolism.
- Untreated PKU can lead to severe neurocognitive and behavioral deficits.
- This review focuses on pediatric PKU management in Turkey.
Purpose of the Study:
- To review current clinical experiences and expert recommendations for PKU diagnosis, treatment, and follow-up in Turkey.
- To address identified management gaps in pediatric PKU care.
- To formulate evidence-based statements for PKU management.
Main Methods:
- Convened advisory board meetings with four leading experts in 2016 and 2017.
- Conducted an online update meeting in January 2021 for final consensus.
- Reviewed Turkish and international literature on PKU management.
Main Results:
- Recommended diagnostic cut-off for dried blood spots at 2 mg/dl and treatment cut-off at 6 mg/dl.
- Advocated for age-related safe protein intake with L-amino acid supplements, including compensatory factors.
- Stressed the importance of regular cognitive evaluations and specific phenylalanine targets for pregnant women (< 5 mg/dl).
Conclusions:
- Standardizing diagnostic and treatment thresholds is crucial for long-term PKU management.
- Early diagnosis and initiation of treatment are paramount.
- PKU follow-up is an evolving process requiring dynamic clinical practice adjustments.
Background:
Phenylketonuria (PKU), is an autosomal recessive disease leading to the conversion defect of phenylalanine (Phe) into tyrosine. Severe neurocognitive and behavioral outcomes are observed in untreated cases. The present paper aims to review clinical experiences and expert recommendations in diagnosis, treatment, and follow-up of pediatric PKU patients in Turkey.
Methods:
Two advisory board meetings were held in the year 2016 and 2017 with contributions of four leading experts in this field, and an online update meeting was held for final decisions about statements, and conclusions in January 2021. Considering management gaps in diagnosis, treatment, and follow-up of PKU, discussion points are defined. The Committee members then reviewed the Turkish and general literature and the final statements were formulated.
Results:
The diagnostic cut-off for dried blood spots should remain at 2 mg/dl. Treatment cut-off value is acceptable at 6 mg/dl. Compliance with an ideal follow-up list is strongly recommended. Total protein intake should not be limited. Age-related safe levels of protein intake should be encouraged with an additional 40% from L-amino acids supplements, a 20% compensatory factor to account for the digestibility and utilization of amino acids from the supplement, and a further 20% compensation to optimize Phe control. Cognitive impairment and intelligence quotient evaluations should be performed at least twice before 3 years of age. In pregnant women, the target Phe level should be < 5 mg/dl, and they should be followed-up weekly in the first trimester, then every 2 weeks after organogenesis. Novel pharmacological treatments are promising, but some of them have limitations for our country.
Conclusions:
Early diagnosis and treatment initiation; determination and standardization of diagnostic and treatment thresholds; treatment modalities and follow-up parameters are significant steps in treating PKU in the long term. PKU follow-up is a dynamic process with uncertainties and differences in clinical practice.
Related Concept Videos
01:20Inborn Errors of Metabolism
01:21Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
01:28Chronic Kidney Disease III: Interprofessional Care
02:27Background and Environment Affect Phenotype
An example of how genetic background affects phenotype can be seen in horses. The Extension gene in horses is responsible for their coat color. A wild-type gene (EE) produces black pigment in the coat, while a mutant gene (ee) produces red pigment. A...